We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

New Imaging Technique Detects Aggressive Lung and Prostate Cancers

By MedImaging International staff writers
Posted on 02 Jul 2024
Print article
Image: The DLL3-targeting technology can detect some cancers that would likely be missed by more conventional imaging (Photo courtesy of Radiochemistry & Molecular Imaging Probe Core Facility)
Image: The DLL3-targeting technology can detect some cancers that would likely be missed by more conventional imaging (Photo courtesy of Radiochemistry & Molecular Imaging Probe Core Facility)

Small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) are types of neuroendocrine cancers, which develop in hormone-producing cells. SCLC is known for its rapid spread to other regions and lymph nodes in the chest. The five-year survival rate stands at 18% when it is diagnosed after it has spread beyond the lungs. NEPC, while rare, is highly lethal and lacks effective standard treatments. It may appear as a new cancer, referred to as “de novo,” or develop from more common prostate adenocarcinoma, often due to the effects of treatments like hormone therapy or chemotherapy. NEPCs are challenging to detect and usually require biopsies for diagnosis, posing an increasing challenge in prostate cancer management. However Now, a new imaging technology has been shown to enhance the detection of metastatic SCLC and NEPC, which conventional imaging methods might miss.

This advanced imaging method, developed at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA), utilizes a radioactive tracer designed to bind to a specific cancer cell ligand known as DLL3, enhancing the visibility of these cells on PET scans. DLL3 is predominantly expressed in aggressive forms of SCLC and NEPC, aiding in the identification of patients who could benefit from new DLL3-targeting drugs currently under clinical evaluation. Furthermore, researchers are exploring ways to couple these drugs with radioactive materials to create a targeted treatment that spares healthy cells while eliminating cancer cells.

Named [89Zr]Zr-DFO-SC16.56, this imaging agent is a significant advancement in the field of theranostics, which combines diagnostic and therapeutic capabilities in a single agent. The imaging agent is injected into the body by a nuclear medicine physician, followed by its absorption by cancer cells that express DLL3. This process allows physicians to use PET scans to determine the extent of the cancer and guide treatment decisions. This agent not only detects minute metastases to the brain but may also be applicable to other cancers like thyroid cancer and neuroblastoma. Initial results from a pilot study published in The Lancet Oncology have shown that [89Zr]Zr-DFO-SC16.56 reliably identifies cancer cells with DLL3 in 18 patients, without raising safety issues. Plans are underway to further evaluate this agent in a larger cohort, with MSK receiving multiple grants to advance and validate this DLL3-focused technology.

“DLL3-targeting technology could be the next generation of theranostics, guiding new treatments for patients with small cell lung cancer or neuroendocrine prostate cancers who otherwise would have run out of options,” said MSK radiochemist Jason S. Lewis, PhD.

Related Links:
Memorial Sloan Kettering Cancer Center

Gold Member
Solid State Kv/Dose Multi-Sensor
Mobile Digital X-Ray System
MobileDiagnost wDR 2.1
Drape Barrier
Double Pivot Swing Arm Drape
Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform

Print article



view channel
Image: The pathways in the brain highlighted are those most affected by concussion (Photo courtesy of Benjamin Hacker et al)

AI Model Diagnoses Traumatic Brain Injury from MRI Scans With 99% Accuracy

A concussion is a type of traumatic brain injury that may lead to temporary disruptions in brain function. Occurring from incidents such as sports injuries, whiplash, or a simple bump to the head, many... Read more


view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.